Payment overview · 2025
General Payments
$226.63
25 reported records · 4 companies
Healthcare provider profile · identity verified
Brian Todd Robertson, DO
Allopathic & Osteopathic Physicians|Internal Medicine · HANOVER, IN · NPI 1023544749
Verified facts
What the public records show
CMS Open Payments records show Brian Todd Robertson, DO received $226.63 in general payments during 2025 across 25 reported records.
ABBVIE INC. accounted for 69.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Jardiance, Qulipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Caplyta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $157.36 | 69.4% | 19 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.70 | 16.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.29 | 7.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.28 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $188.93 | 23 |
| Education | $37.70 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $134.15 | 16 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.21 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.21 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.29 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 102 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
102 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 681 | 166 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 663 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 541 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 528 | 166 |
| Losartan Potassium | Losartan Potassium | 512 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 486 | 144 |
| Furosemide | Furosemide | 452 | 149 |
| Alprazolam | Alprazolam | 434 | 78 |
| Omeprazole | Omeprazole | 431 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 427 | 129 |
| Lisinopril | Lisinopril | 394 | 118 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 357 | 108 |
| Potassium Chloride | Potassium Chloride | 331 | 100 |
| Meloxicam | Meloxicam | 327 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 327 | 107 |
| Tramadol Hcl | Tramadol Hcl | 304 | 79 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 298 | 47 |
| Trazodone Hcl | Trazodone Hcl | 281 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 275 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 271 | 85 |
| Metformin Hcl | Metformin Hcl | 270 | 85 |
| Methylprednisolone | Methylprednisolone | 270 | 195 |
| Ozempic | Semaglutide | 264 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 252 | 62 |
| Mounjaro | Tirzepatide | 251 | 54 |
| Farxiga | Dapagliflozin Propanediol | 233 | 49 |
| Azithromycin | Azithromycin | 229 | 169 |
| Eliquis | Apixaban | 198 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 185 | 59 |
| Sertraline Hcl | Sertraline Hcl | 182 | 53 |
| Celecoxib | Celecoxib | 174 | 50 |
| Pregabalin | Pregabalin | 158 | 42 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 149 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 137 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 47 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 128 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 45 |
| Spironolactone | Spironolactone | 118 | 37 |
| Carvedilol | Carvedilol | 114 | 35 |
| Prednisone | Prednisone | 114 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 114 | 26 |
| Ondansetron Odt | Ondansetron | 110 | 48 |
| Simvastatin | Simvastatin | 109 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 25 |
| Vraylar | Cariprazine Hcl | 102 | 13 |
| Glipizide | Glipizide | 100 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 100 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 23 |
| Allopurinol | Allopurinol | 97 | 28 |
| Bumetanide | Bumetanide | 97 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 97 | 67 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 94 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 26 |
| Clonazepam | Clonazepam | 89 | 20 |
| Jardiance | Empagliflozin | 89 | 24 |
| Montelukast Sodium | Montelukast Sodium | 88 | 25 |
| Atenolol | Atenolol | 83 | 25 |
| Fluconazole | Fluconazole | 82 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 81 | 27 |
| Sucralfate | Sucralfate | 79 | 32 |
| Baclofen | Baclofen | 78 | 16 |
| Buspirone Hcl | Buspirone Hcl | 74 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 22 |
| Levofloxacin | Levofloxacin | 72 | 57 |
| Amoxicillin | Amoxicillin | 70 | 55 |
| Famotidine | Famotidine | 68 | 19 |
| Finasteride | Finasteride | 67 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 53 |
| Linzess | Linaclotide | 65 | 15 |
| Synthroid | Levothyroxine Sodium | 65 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 46 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 61 | suppressed |
| Temazepam | Temazepam | 61 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 19 |
| Ezetimibe | Ezetimibe | 59 | 17 |
| Glimepiride | Glimepiride | 59 | 18 |
| Alendronate Sodium | Alendronate Sodium | 57 | 15 |
| Mupirocin | Mupirocin | 57 | 46 |
| Diazepam | Diazepam | 56 | 14 |
| Promethazine Hcl | Promethazine Hcl | 55 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 17 |
| Lorazepam | Lorazepam | 54 | 15 |
| Cephalexin | Cephalexin | 53 | 41 |
| Digoxin | Digoxin | 53 | 13 |
| Klor-Con M20 | Potassium Chloride | 53 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 15 |
| Donepezil Hcl | Donepezil Hcl | 51 | 15 |
| Ibuprofen | Ibuprofen | 51 | 12 |
| Warfarin Sodium | Warfarin Sodium | 51 | 16 |
| Meclizine Hcl | Meclizine Hcl | 49 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 13 |
| Nystatin | Nystatin | 47 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 11 |
| Valsartan | Valsartan | 46 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 12 |
| Cholestyramine | Cholestyramine (With Sugar) | 43 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 16 |
| Topiramate | Topiramate | 43 | 12 |
| Cefdinir | Cefdinir | 42 | 30 |
| Klor-Con M10 | Potassium Chloride | 42 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | 14 |
| Metformin Hcl Er | Metformin Hcl | 40 | 13 |
| Midodrine Hcl | Midodrine Hcl | 40 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 39 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 19 |
| Scopolamine | Scopolamine | 37 | suppressed |
| Nifedipine Er | Nifedipine | 35 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | 11 |
| Humira Pen | Adalimumab | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 15 |
| Varenicline Tartrate | Varenicline Tartrate | 30 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 11 |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | 16 |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Qulipta | Atogepant | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 15 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Ofloxacin | Ofloxacin | 21 | 13 |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Caplyta | Lumateperone Tosylate | 18 | suppressed |
| Nabumetone | Nabumetone | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | 15 |
| Estradiol | Estradiol | 17 | suppressed |
| Humira(Cf) | Adalimumab | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 17 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Teriparatide | Teriparatide | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Volnea | Desog-E.Estradiol/E.Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $226.63 · 25 records | ABBVIE INC. | CAPLYTA, JARDIANCE, QULIPTA, UBRELVY, VOQUEZNA, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error